

SCOPE: ALS (<i>continuation only</i>), CCT,	
MEDICATION:	HEPARIN
INTERVENTION:	<p><u>Classification:</u> Anticoagulant</p> <p><u>Actions:</u> Potentiates the action of antithrombin III and thereby inactivates thrombin (as well as activated coagulation factors IX, X, XI, XII, and plasmin) and prevents the conversion of fibrinogen to fibrin; heparin also stimulates release of lipoprotein lipase (lipoprotein lipase hydrolyzes triglycerides to glycerol and free fatty acids)</p> <p><u>Contraindications:</u></p> <ul style="list-style-type: none"> • Hypersensitivity to heparin • Severe thrombocytopenia • History of heparin-induced thrombocytopenia (HIT) • Uncontrolled active bleeding except when due to DIC <p><u>Precautions:</u></p> <ul style="list-style-type: none"> • Bleeding may occur • Thrombocytopenia may occur • Can cause hyperkalemia <p><u>Dosage:</u></p> <ol style="list-style-type: none"> I. <u>STEMI/NSTEMI/ACS or Anticoagulation:</u> <ol style="list-style-type: none"> a. Adult/Pediatric <ol style="list-style-type: none"> i. IV/IO: Per on-line medical direction or sending facility normogram II. <u>UVC/UAC:</u> <ol style="list-style-type: none"> a. Neonate: <ol style="list-style-type: none"> i. 1unit/ml <p><u>Onset of Action:</u> Immediate</p> <p><u>Duration:</u> ~1-2 hrs</p> <p><u>Adverse Effects:</u> Thrombocytopenia, chest pain, shock, thrombosis</p> <p><u>Special Considerations:</u></p> <ol style="list-style-type: none"> I. Dose must be double verified prior to administration

If this is a patient care policy, the information contained herein is used to provide guidance in the care of patients, but should not, and does not replace or preclude the use of clinical judgment.

<i>FOR OFFICE USE ONLY</i>	
Originator:	Original Date:
Revised Date:	
Effective Date: 06/01/18	Page 1 of 1